New contract marks the 20th state in the nation where Syra has active contracts CARMEL, Ind., May 28, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it has been awarded a contract by the Health Care Authority (HCA) in Washington State to provide essential behavioral health and recovery training and support services. This ...

CARMEL, Ind., May 20, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it has been awarded a one-year contract with annual extensions for up to five years to provide Special Education (SPED) Psychologist Services for the Greenville County School District in South Carolina. The SPED Psychologist services provided by Syra He ...

Syra Health Corp. (NASDAQ:SYRA) Q1 2024 Earnings Conference Call May 9, 2024 9:00 AM ET Company Participants Deepika Vuppalanchi - Chief Executive Officer Priya Prasad - Chief Financial Officer Operator Good morning, everyone and thank you for joining us for Syra Health First Quarter 2024 Financial Results Conference Call. Joining us on today’s call is Dr. Deepika Vuppalanchi, CEO of Syra Health and Priya Prasad, Syra’s Chief Financial Officer. At the conclusion of today’s prepared remarks, management will ...

Exhibit 99.1 The Company anticipates full-year 2024 revenue of $9 to $11 million, representing growth of 64%-100% versus 2023. Due to the implementation cycle of customers, the Company expects the majority of its contract revenues to be realized in the second half of 2024. Syra Health Announces First Quarter 2024 Financial Results, Led By Strong Revenue Growth of 47%. Conference call will be held today, Thursday, May 9 at 9:00 am ET Carmel, IN, May 9, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), ("S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 85-4027995 (State or ...

Exhibit 99.1 Syra Health Announces Fourth-Quarter and Full-Year 2023 Financial Results. Projects 2024 Revenue Growth of 64% to 100%. Conference call will be held today, Monday, March 25 at 9:00am ET Carmel, IN, March 25, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, today announced its financial results for the fourth quarter and fiscal year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______. Commission File Number 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organizati ...

Syra Health Corp. (NASDAQ:SYRA) Q4 2023 Earnings Call Transcript March 25, 2024 9:00 AM ET Company Participants Ben Shamsian - IR Deepika Vuppalanchi - CEO Sandeep Allam - Executive Chairman and President Priya Prasad - CFO Operator Good morning, ladies and gentlemen, and welcome to Syra Health Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all lines are in a listen-only mode. [Operator Instructions] This call is being recorded on Monday, March 25, 2024. I would now like ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 85-4027995 (Stat ...